Analyst Viewpoint
Rise in prevalence of cervical cancer is a prominent factor that is fostering cervical dysplasia market development. Early detection and treatment can help restrict the growth of cancer-causing cells. Increase in awareness about the importance of early detection and screening of cancer among the population is driving market expansion.
Governments of several countries are investing significantly in healthcare infrastructure development in order to improve the availability of treatments and reimbursement policies. Cost-effectiveness of screening tests and accuracy of results are also augmenting market progress. Leading players are adopting the latest cervical dysplasia market trends and launching new test kits and introducing advanced treatments in order to strengthen their industry position.
Cervical dysplasia refers to abnormal changes in the cells on the surface of the cervix. The changes are not cancer, but can lead to cancer of the cervix if not treated.
Types of cervical dysplasia include low-grade and high-grade cervical dysplasia. Low-grade cervical dysplasia progresses gradually, and often, the condition goes away without any treatment. High-grade cervical dysplasia can lead to cervical cancer. Cervical dysplasia may not cause any symptoms until it develops into cancer.
Common symptoms that may occur are abnormal bleeding between menstrual periods, abnormal bleeding after sexual intercourse, heavy menstrual bleeding, and menstrual bleeding that may last longer than usual.
Incidence of moderate or severe cervical dysplasia could require immediate treatment such as cryosurgery to freeze off the abnormal cervical tissue and loop electrosurgical excision procedure (LEEP) to burn off the abnormal cells with an electric looped wire.
Cervical cancer refers to growth of cells that start in the cervix. Human Papillomavirus (HPV) is one of the primary causes of cervical cancer. Rise in prevalence of cervical cancer due to long-lasting infections such as HPV and Sexually Transmitted Diseases (STDs) is driving the cervical dysplasia market value. Cervical dysplasia can be treated if diagnosed at the initial state.
Increase in awareness about the importance of diagnostic tests and cancer screening is fueling the cervical dysplasia market revenue. Regular visits to gynecologists and screening processes can help diagnose cervical dysplasia at the initial state. Cervical dysplasia can affect reproductive parts. Efficient future analysis of cervical dysplasia would enable healthcare professionals to come up with early diagnostic tests and avoid the occurrence of cervical cancer.
According to the World Health Organization, cervical cancer is one of the most common cancers in women globally. The data estimated around 604,000 new cases and 342,000 deaths in 2020.
Governments of various countries across the globe are conducting awareness camps, and increasing the number of screenings and availability of treatments for cervical dysplasia. Thus, awareness regarding the importance of routine screening processes such as HPV testing and Pap smear is rising across the globe.
Government initiatives regarding the development of HPV vaccination programs to identify and treat high-risk strains of the virus are also bolstering market dynamics. Furthermore, healthcare organizations are focusing on conducting early diagnosis of cervical dysplasia symptoms in certain age groups in order to provide appropriate cervical dysplasia treatment.
As per a report by the World Health Organization, HPV infection causes about 5.0% of all cancers globally. Approximately 625,600 women and 69,400 men are afflicted with HPV-related cancer each year.
Cervical dysplasia diagnosis is conducted by healthcare professionals on the occurrence of symptoms such as intense pelvic pain, irregular bleeding between menstrual cycles, prolonged menstrual cycles, or unusually heavy blood flow during menstruation.
Based on diagnosis, the diagnostic tests segment is likely to hold the largest cervical cancer diagnostic market share in the near future due to the increase in prevalence of cervical cancer across the globe.
Pap smear and HPV tests are usually conducted to detect cervical dysplasia among patients. Cost-effectiveness and accuracy of results are crucial factors driving the demand for HPV diagnostic tests.
North America is projected to lead the global landscape during the forecast period. Presence of developed healthcare infrastructure and increase in awareness about screening programs are fueling the cervical dysplasia market demand in the region.
Availability of favorable reimbursement policies is also encouraging those afflicted to opt for regular screening. The Centers for Medicare & Medicaid Services covers a screening pelvic examination and Pap test for female beneficiaries at 12 to 24-month intervals. The reimbursement varies and is based on specific risk factors.
According to cervical dysplasia market analysis, the sector in Asia Pacific is anticipated to grow at a fast pace in the next few years due to the rapid development of healthcare facilities in the region. Healthcare organizations in Asia pacific are investing in research and development activities to enhance the availability of treatments for several chronic diseases and cancers. They are also focusing on conducting regular cervical dysplasia screening programs.
Leading players in the industry are focusing on launching new test kits that facilitate faster results. They are also engaging in collaborations to increase their market reach and provide global services.
The cervical dysplasia market report highlights some of the prominent players such as F. Hoffmann La-Roche Ltd., QIAGEN, Becton, Dickinson and Company, OncoHealth Corporation, Quest Diagnostics, Inc., Hologic, Inc., and Abbott Healthcare Pvt. Ltd.
These companies have been profiled in the cervical dysplasia market research report based on various parameters such as company overview, business segments, product portfolio, recent developments, business strategies, and financial overview.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 581.8 Mn |
| Market Forecast (Value) in 2031 | US$ 962.0 Mn |
| Growth Rate (CAGR) | 5.6% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Tons | US$ Mn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 581.8 Mn in 2022
It is projected to register a CAGR of 5.6% from 2023 to 2031
Increase in prevalence of cervical cancer and government initiatives in the healthcare sector
North America was the most lucrative region in 2022
F. Hoffmann La-Roche Ltd., QIAGEN, Becton, Dickinson and Company, OncoHealth Corporation, Quest Diagnostics, Inc., Hologic, Inc., and Abbott Healthcare Pvt. Ltd.
1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cervical Dysplasia Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cervical Dysplasia Market Analysis and Forecast, 2023-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. List of Tests Conducted to Diagnose Cervical Dysplasia
5.3. Disease Prevalence & Incidence Rate Globally with Key Countries
5.4. COVID-19 Pandemic Impact on Industry
6. Cervical Dysplasia Market Analysis and Forecast, by Diagnosis
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Diagnosis, 2023-2031
6.3.1. Diagnostic Test
6.3.1.1. Pap Smear Test
6.3.1.2. HPV Test
6.3.1.3. Biopsy
6.3.2. Diagnostic Device
6.3.2.1. Colposcopy
6.4. Market Attractiveness, by Diagnosis
7. Global Cervical Dysplasia Market Analysis and Forecast, by End-user
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2023-2031
7.3.1. Hospitals
7.3.2. Diagnostic Centers
7.3.3. Private Gynecologist Offices
7.3.4. Research & Academic Institutes
7.3.5. Ambulatory Surgical Centers
7.4. Market Attractiveness, by End-user
8. Global Cervical Dysplasia Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2023-2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Cervical Dysplasia Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Diagnosis, 2023-2031
9.2.1. Diagnostic Test
9.2.1.1. Pap Smear Test
9.2.1.2. HPV Test
9.2.1.3. Biopsy
9.2.2. Diagnostic Device
9.2.2.1. Colposcopy
9.3. Market Value Forecast, by End-user, 2023-2031
9.3.1. Hospitals
9.3.2. Diagnostic Centers
9.3.3. Private Gynecologist Offices
9.3.4. Research & Academic Institutes
9.3.5. Ambulatory Surgical Centers
9.4. Market Value Forecast, by Country, 2023-2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Diagnosis
9.5.2. By End-user
9.5.3. By Country
10. Europe Cervical Dysplasia Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Diagnosis, 2023-2031
10.2.1. Diagnostic Test
10.2.1.1. Pap Smear Test
10.2.1.2. HPV Test
10.2.1.3. Biopsy
10.2.2. Diagnostic Device
10.2.2.1. Colposcopy
10.3. Market Value Forecast, by End-user, 2023-2031
10.3.1. Hospitals
10.3.2. Diagnostic Centers
10.3.3. Private Gynecologist Offices
10.3.4. Research & Academic Institutes
10.3.5. Ambulatory Surgical Centers
10.4. Market Value Forecast, by Country/Sub-region, 2023-2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Diagnosis
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Cervical Dysplasia Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Diagnosis, 2023-2031
11.2.1. Diagnostic Test
11.2.1.1. Pap Smear Test
11.2.1.2. HPV Test
11.2.1.3. Biopsy
11.2.2. Diagnostic Device
11.2.2.1. Colposcopy
11.3. Market Value Forecast, by End-user, 2023-2031
11.3.1. Hospitals
11.3.2. Diagnostic Centers
11.3.3. Private Gynecologist Offices
11.3.4. Research & Academic Institutes
11.3.5. Ambulatory Surgical Centers
11.4. Market Value Forecast, by Country/Sub-region, 2023-2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Diagnosis
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America Cervical Dysplasia Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Diagnosis, 2023-2031
12.2.1. Diagnostic Test
12.2.1.1. Pap Smear Test
12.2.1.2. HPV Test
12.2.1.3. Biopsy
12.2.2. Diagnostic Device
12.2.2.1. Colposcopy
12.3. Market Value Forecast, by End-user, 2023-2031
12.3.1. Hospitals
12.3.2. Diagnostic Centers
12.3.3. Private Gynecologist Offices
12.3.4. Research & Academic Institutes
12.3.5. Ambulatory Surgical Centers
12.4. Market Value Forecast, by Country/Sub-region, 2023-2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Diagnosis
12.5.2. By End-user
12.5.3. By Country/Sub-region
13. Middle East & Africa Cervical Dysplasia Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Diagnosis, 2023-2031
13.2.1. Diagnostic Test
13.2.1.1. Pap Smear Test
13.2.1.2. HPV Test
13.2.1.3. Biopsy
13.2.2. Diagnostic Device
13.2.2.1. Colposcopy
13.3. Market Value Forecast, by End-user, 2023-2031
13.3.1. Hospitals
13.3.2. Diagnostic Centers
13.3.3. Private Gynecologist Offices
13.3.4. Research & Academic Institutes
13.3.5. Ambulatory Surgical Centers
13.4. Market Value Forecast, by Country/Sub-region, 2023-2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Diagnosis
13.5.2. By End-user
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. F. Hoffmann La-Roche Ltd.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. QIAGEN
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Becton, Dickinson and Company
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. OncoHealth Corporation
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Quest Diagnostics, Inc.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Hologic, Inc.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Abbott Healthcare Pvt. Ltd.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
List of Tables
Table 01: Global Cervical Dysplasia Market Value (US$ Mn) Forecast, by Diagnosis, 2023-2031
Table 02: Global Cervical Dysplasia Market Value (US$ Mn) Forecast, by End-user, 2023-2031
Table 03: Global Cervical Dysplasia Market Value (US$ Mn) Forecast, by Region, 2023-2031
Table 04: North America Cervical Dysplasia Market Value (US$ Mn) Forecast, by Country, 2023-2031
Table 05: North America Cervical Dysplasia Market Value (US$ Mn) Forecast, by Diagnosis, 2023-2031
Table 06: North America Cervical Dysplasia Market Value (US$ Mn) Forecast, by End-user, 2023-2031
Table 07: Europe Cervical Dysplasia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
Table 08: Europe Cervical Dysplasia Market Value (US$ Mn) Forecast, by Diagnosis, 2023-2031
Table 09: Europe Cervical Dysplasia Market Value (US$ Mn) Forecast, by End-user 2023-2031
Table 10: Asia Pacific Cervical Dysplasia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
Table 11: Asia Pacific Cervical Dysplasia Market Value (US$ Mn) Forecast, by Diagnosis, 2023-2031
Table 12: Asia Pacific Cervical Dysplasia Market Value (US$ Mn) Forecast, by End-user, 2023-2031
Table 13: Latin America Cervical Dysplasia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
Table 14: Latin America Cervical Dysplasia Market Value (US$ Mn) Forecast, by Diagnosis, 2023-2031
Table 15: Latin America Cervical Dysplasia Market Value (US$ Mn) Forecast, by End-user 2023-2031
Table 16: Middle East & Africa Cervical Dysplasia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
Table 17: Middle East & Africa Cervical Dysplasia Market Value (US$ Mn) Forecast, by Diagnosis, 2023-2031
Table 18: Middle East & Africa Cervical Dysplasia Market Value (US$ Mn) Forecast, by End-user 2023-2031
List of Figures
Figure 01: Global Cervical Dysplasia Market Value (US$ Mn) Forecast, 2023-2031
Figure 02: Global Cervical Dysplasia Market Value Share, by Diagnosis, 2023
Figure 03: Global Cervical Dysplasia Market Value Share, by End-user, 2023
Figure 04: Global Cervical Dysplasia Market Value Share Analysis, by Diagnosis, 2023 and 2031
Figure 05: Global Cervical Dysplasia Market Attractiveness Analysis, by Diagnosis, 2023-2031
Figure 06: Global Cervical Dysplasia Market Value Share Analysis, by End-user, 2023 and 2031
Figure 07: Global Cervical Dysplasia Market Attractiveness Analysis, by End-user 2023-2031
Figure 08: Global Cervical Dysplasia Market Value Share Analysis, by Region, 2023 and 2031
Figure 09: Global Cervical Dysplasia Market Attractiveness Analysis, by Region, 2023-2031
Figure 10: North America Cervical Dysplasia Market Value (US$ Mn) Forecast, 2023-2031
Figure 11: North America Cervical Dysplasia Market Value Share Analysis, by Country, 2023 and 2031
Figure 12: North America Cervical Dysplasia Market Attractiveness Analysis, by Country, 2023-2031
Figure 13: North America Cervical Dysplasia Market Value Share Analysis, by Diagnosis, 2023 and 2031
Figure 14: North America Cervical Dysplasia Market Attractiveness Analysis, by Diagnosis, 2023-2031
Figure 15: North America Cervical Dysplasia Market Value Share Analysis, by End-user, 2023 and 2031
Figure 16: North America Cervical Dysplasia Market Attractiveness Analysis, by End-user 2023-2031
Figure 17: Europe Cervical Dysplasia Market Value (US$ Mn) Forecast, 2023-2031
Figure 18: Europe Cervical Dysplasia Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 19: Europe Cervical Dysplasia Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 20: Europe Cervical Dysplasia Market Value Share Analysis, by Diagnosis, 2023 and 2031
Figure 21: Europe America Cervical Dysplasia Market Attractiveness Analysis, by Diagnosis, 2023-2031
Figure 22: Europe Cervical Dysplasia Market Value Share Analysis, by End-user, 2023 and 2031
Figure 23: Europe Cervical Dysplasia Market Attractiveness Analysis, by End-user 2023-2031
Figure 24: Asia Pacific Cervical Dysplasia Market Value (US$ Mn) Forecast, 2023-2031
Figure 25: Asia Pacific Cervical Dysplasia Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 26: Asia Pacific Cervical Dysplasia Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 27: Asia Pacific Cervical Dysplasia Market Value Share Analysis, by Diagnosis, 2023 and 2031
Figure 28: Asia Pacific America Cervical Dysplasia Market Attractiveness Analysis, by Diagnosis, 2023-2031
Figure 29: Asia Pacific Cervical Dysplasia Market Value Share Analysis, by End-user, 2023 and 2031
Figure 30: Asia Pacific Cervical Dysplasia Market Attractiveness Analysis, by End-user 2023-2031
Figure 31: Latin America Cervical Dysplasia Market Value (US$ Mn) Forecast, 2023-2031
Figure 32: Latin America Cervical Dysplasia Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 33: Latin America Cervical Dysplasia Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 34: Latin America Cervical Dysplasia Market Value Share Analysis, by Diagnosis, 2023 and 2031
Figure 35: Latin America Cervical Dysplasia Market Attractiveness Analysis, by Diagnosis, 2023-2031
Figure 36: Middle East & Africa Cervical Dysplasia Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 37: Middle East & Africa Cervical Dysplasia Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 38: Middle East & Africa America Cervical Dysplasia Market Value Share Analysis, by Diagnosis, 2023-2031
Figure 39: Middle East & Africa America Cervical Dysplasia Market Attractiveness Analysis, by Diagnosis, 2023-2031
Figure 40: Middle East & Africa Cervical Dysplasia Market Value Share Analysis, by End-user, 2023 and 2031
Figure 41: Middle East & Africa Cervical Dysplasia Market Attractiveness Analysis, by End-user 2023-2031
Figure 42: Global Cervical Dysplasia Market Share Analysis, by Company (2022)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Cervical Dysplasia Market
*86 figures and 60 tables includes